ANL Adlai Nortye Group Ltd. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1944552 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | $5.00M | — | $45.73M |
| R&D expense | $44.91M | $58.15M | $54.49M | $42.10M |
| SG&A expense | $9.95M | $15.29M | $13.04M | — |
| Operating income | -$52.93M | -$72.55M | -$67.27M | -$8.65M |
| Interest expense | $1.94M | $791,000 | $433,000 | $1.34M |
| Pretax income | -$51.87M | -$109.23M | -$58.79M | -$56.68M |
| Income tax | — | $643,000 | — | — |
| Net income | -$51.87M | -$109.23M | -$58.79M | -$56.68M |
| EBITDA | -$52.42M | -$72.09M | -$66.66M | — |
| EPS (basic) | -0.54 | -2.52 | -2.31 | -2.23 |
| EPS (diluted) | -0.54 | -2.52 | -2.31 | -2.23 |
| Weighted avg. shares (diluted) | 95.78M | 43.34M | 25.44M | 25.44M |
| Balance sheet | ||||
| Cash & equivalents | $60.90M | $91.49M | $42.76M | $64.13M |
| Current assets | $64.06M | $101.19M | $66.30M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $1.74M | $2.65M | $3.71M | $3.65M |
| Intangibles | $40,000 | $63,000 | $89,000 | — |
| Total assets | $71.27M | $130.19M | $72.59M | — |
| Current liabilities | $45.36M | $49.67M | $312.65M | — |
| Short-term debt | $26.33M | $30.36M | $4.31M | — |
| Total liabilities | $45.78M | $55.14M | $313.89M | — |
| Shareholders' equity | $25.48M | $75.05M | -$241.29M | -$185.43M |
| Shares outstanding | — | — | 40.44M | — |
| Cash flow statement | ||||
| Operating cash flow | -$51.82M | -$56.65M | -$43.22M | -$3.03M |
| Capital expenditure | $170,000 | $200,000 | $1.25M | $1.02M |
| Free cash flow | -$51.99M | -$56.85M | -$44.47M | -$4.05M |
| Investing cash flow | $28.07M | -$10.95M | $28.38M | -$54.86M |
| Financing cash flow | -$6.58M | $116.24M | -$6.78M | $97.20M |
| Depreciation & amortization | $510,000 | $465,000 | $609,000 | — |
| Stock-based compensation | $2.45M | $4.33M | $6.08M | $3.39M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.